Cell-Specific Vulnerability of Human Glioblastoma and Astrocytoma Cells to Mephedrone-An In Vitro Study
Marta Marszalek-Grabska1, Marta Kinga Lemieszek2, Michal Chojnacki2
1Department of Experimental and Clinical Pharmacology, Medical University, Jaczewskiego 8b, 20-090 Lublin, Poland.
Abstract:
Glioblastoma multiforme is a highly aggressive intrinsic brain tumor with a very poor survival rate. The main treatment for cancer is surgery combined with postoperative radiotherapy and temozolomide chemotherapy. Since the outcomes of treatment are unsatisfactory, the search for more effective drugs is crucial. Our previous study indicated that mephedrone, a synthetic cathinone, reduced neuron and astrocyte viability and oligodendrocyte proliferation. The aim of the present study was to investigate the effect of mephedrone on selected human glioblastoma (LN-18, LN-229, T98G) and human anaplastic astrocytoma (MOGGCCM) cell lines. The effects of mephedrone on cell viability and proliferation, DNA synthesis, cell cycle progression and the type of cell death were studied. Our results showed that mephedrone possesses potential anticancer activity. The viability and proliferation of all four human glioblastoma and human anaplastic astrocytoma cell lines used were decreased in a concentration-dependent manner. Studies conducted on LN-18 and T98G cells confirmed the significant antiproliferative properties of mephedrone, which reduced DNA synthesis and affected cell cycle progression. Microscopic evaluation supported the antiproliferative effect of the tested compounds. Moreover, substantial cytoplasmic vacuolization in the LN-18 cell line was revealed. This finding may indicate the potential of mephedrone in anticancer therapy.
Insights
Mephedrone, a synthetic cathinone, demonstrates potential anticancer activity against glioblastoma and astrocytoma cell lines. This research indicates mephedrone may offer a novel therapeutic avenue for brain cancer treatment.
Area of Science:
- Neuro-oncology
- Pharmacology
- Cell Biology
Background:
- Glioblastoma multiforme is an aggressive brain tumor with poor prognosis.
- Current treatments (surgery, radiotherapy, chemotherapy) have unsatisfactory outcomes.
- Novel therapeutic agents are urgently needed for glioblastoma treatment.
Purpose of the Study:
- To investigate the anticancer effects of mephedrone on human glioblastoma and anaplastic astrocytoma cell lines.
- To evaluate mephedrone's impact on cell viability, proliferation, DNA synthesis, cell cycle, and cell death.
- To explore mephedrone as a potential therapeutic agent for brain tumors.
Main Methods:
- Treatment of human glioblastoma (LN-18, LN-229, T98G) and anaplastic astrocytoma (MOGGCCM) cell lines with mephedrone.
- Assessment of cell viability, proliferation, DNA synthesis, and cell cycle progression.
- Microscopic evaluation of cellular morphology, including cytoplasmic vacuolization.
Main Results:
- Mephedrone significantly reduced the viability and proliferation of all tested cell lines in a dose-dependent manner.
- Mephedrone demonstrated antiproliferative effects by inhibiting DNA synthesis and altering cell cycle progression in LN-18 and T98G cells.
- Microscopic analysis revealed cytoplasmic vacuolization in LN-18 cells, suggesting a specific mechanism of action.
Conclusions:
- Mephedrone exhibits significant anticancer properties against glioblastoma and anaplastic astrocytoma cells.
- The findings suggest mephedrone has potential as a novel therapeutic agent in brain cancer treatment.
- Further research is warranted to elucidate the precise mechanisms and therapeutic potential of mephedrone.
More Related Videos
10:13Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
Published on: August 12, 2014
15:04A Neuronal and Astrocyte Co-Culture Assay for High Content Analysis of Neurotoxicity
Published on: May 5, 2009
